查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1572215

细菌性阴道炎治疗药物市场：按药物类型、药物形式、分销管道、患者属性和最终用户划分 - 全球预测 2025-2030

Bacterial Vaginosis Drugs Market by Drug Type (Over-the-counter Drugs, Prescription Drugs), Drug Form (Capsules, Gels, Tablets), Distribution Channel, Patient Demographics, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年细菌性阴道炎治疗药物市场价值为87303万美元，预计到2024年将达到92192万美元，复合年增长率为5.88%，到2030年将达到130320万美元，预计将达到1000万美元。

细菌性阴道炎药物市场包括多种用于治疗细菌性阴道炎（BV）的药物，细菌性阴道炎是一种由阴道菌丛失衡引起的常见阴道疾病。这个市场的驱动因素是解决高盛行率的问题，特别是对育龄妇女的影响，以及对有效、快速和安全治疗的需求。主要用途包括口服和外用製剂中的抗生素和抗菌药物，如甲硝唑和克林霉素。最终用途包括医院、诊所和药局，商业选择扩大了可用性。主要影响因素包括对妇女健康问题认识的提高、医疗保健支出的增加以及药物开发技术的进步。鑑于人们对抗生素抗药性的担忧日益增加，最新的商机凸显了非抗生素疗法和益生菌的开发潜力。此外，利用 DNA 定序技术的个人化医疗创新使我们能够根据每个人的微生物群量身定制治疗方案，以获得更有效的结果。

主要市场统计
基准年[2023] 87303万美元
预测年份 [2024] 9.2192亿美元
预测年份 [2030] 13.032 亿美元
复合年增长率（%） 5.88%

儘管有这些机会，市场仍面临重大限制，例如细菌性阴道炎復发会影响治疗效果，需要进一步研究长期解决方案。新兴市场的耻辱感和对阴道健康问题缺乏认识也对市场渗透构成了挑战。此外，严格的监管要求和与药物开发相关的高成本可能会阻碍新疗法进入市场。创新的治疗领域包括探索微生物组在维持阴道健康中的作用、开发新型益生元和益生菌治疗方法，以及用于早期诊断和提高患者依从性的数位健康工具。市场竞争激烈且充满活力，需要不断适应不断发展的科学发现和患者需求。以客户为中心的方法，优先考虑患者教育和与医疗保健专业人员的合作，有助于推动业务成长并实现有效的市场渗透。

市场动态：揭示快速发展的细菌性阴道炎治疗市场的关键市场洞察

细菌性阴道炎药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球育龄妇女细菌性阴道炎症率不断上升
    • 对细菌性阴道炎有效治疗的认识和需求不断增长
    • 细菌性阴道炎治疗药物研发进展
    • 扩大发展中地区的医疗基础设施以支持细菌性阴道炎的治疗
  • 市场限制因素
    • 新兴市场的认识有限和误诊影响了治疗率
    • 围绕细菌性阴道炎的耻辱和社会禁忌影响患者接受治疗的意愿
  • 市场机会
    • 开拓有针对性的行销策略，以提高女性对细菌性阴道炎和可用治疗方法的认识
    • 利用远端医疗平台提供便利的细菌性阴道炎咨询和处方服务。
    • 进行教育宣传活动以消除细菌性阴道炎并鼓励及时的医疗干预
  • 市场挑战
    • 不同医疗保健系统细菌性阴道炎治疗的报销政策不一致
    • 来自学名药的激烈竞争正在减少品牌细菌性阴道炎药物製造商的市场占有率和盈利。

波特的五力：驾驭细菌性阴道炎药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细菌性阴道炎治疗药物市场的外部影响

外部宏观环境因素在塑造细菌性阴道炎治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细菌性阴道炎治疗药物市场的竞争状况

对细菌性阴道炎治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵细菌性阴道炎治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估细菌性阴道炎治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划细菌性阴道炎治疗药物市场的成功之路

对细菌性阴道炎治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球育龄妇女细菌性阴道炎症率增加
      • 对细菌性阴道炎有效治疗方法的认识和需求不断增长
      • 细菌性阴道炎治疗药物研发进展
      • 扩大开发中地区的医疗基础设施以支持细菌性阴道炎的治疗
    • 抑制因素
      • 缺乏认识和误诊影响新兴市场的治疗率
      • 围绕细菌性阴道炎的耻辱和社会禁忌影响患者接受治疗的意愿
    • 机会
      • 制定有针对性的行销策略，以提高女性对细菌性阴道炎和可用治疗方法的认识
      • 利用远端医疗平台方便获得细菌性阴道炎咨询和处方笺
      • 进行教育宣传活动，消除细菌性阴道炎的污名并鼓励及时的医疗干预
    • 任务
      • 不同医疗保健系统的细菌性阴道炎治疗报销政策不一致
      • 来自学名药的激烈竞争降低了品牌细菌性阴道炎药物製造商的市场占有率和盈利
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类型分類的细菌性阴道炎治疗药物市场

  • 非处方药
    • 防腐剂
    • 益生菌
  • 处方药
    • 口服抗生素
    • 外用抗生素

第七章依剂型分類的细菌性阴道炎治疗药物市场

  • 胶囊
  • 凝胶
    • 药用凝胶
    • 非药物凝胶
  • 药片
    • 发泡
    • 缓释片
    • 速效锭剂

第八章细菌性阴道炎治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第九章细菌性阴道炎治疗药物市场患者细分

  • 成人
  • 长老
  • 青少年

第10章细菌性阴道炎治疗药物市场：依最终用户分类

  • 诊所
  • 居家护理
  • 医院

第十一章 北美和南美细菌性阴道炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太细菌性阴道炎治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲细菌性阴道炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C0104

The Bacterial Vaginosis Drugs Market was valued at USD 873.03 million in 2023, expected to reach USD 921.92 million in 2024, and is projected to grow at a CAGR of 5.88%, to USD 1,303.20 million by 2030.

The market for bacterial vaginosis drugs encompasses a range of therapeutics used to treat bacterial vaginosis (BV), a common vaginal condition caused by an imbalance in the vaginal microbiota. This market is driven by the necessity to address high prevalence rates, particularly impacting women of childbearing age, and the demand for effective, fast-acting, and safe treatments. Key applications involve antibiotics and antimicrobial drugs, such as metronidazole and clindamycin, leveraged in both oral and topical forms. The end-use scope spans across hospitals, clinics, and drug stores, with over-the-counter options expanding accessibility. Key influencing factors include the rising awareness of women's health issues, increased healthcare expenditure, and ongoing advancements in drug development technologies. The latest opportunities highlight the potential in developing non-antibiotic therapies and probiotics, given the increasing concern over antibiotic resistance. Innovations in personalized medicine, leveraging DNA sequencing technologies, can also tailor treatments to individual microbiomes for more effective outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 873.03 million
Estimated Year [2024] USD 921.92 million
Forecast Year [2030] USD 1,303.20 million
CAGR (%) 5.88%

Despite these opportunities, the market faces significant limitations, such as the recurrence of BV, which undermines treatment efficacy and necessitates further research into long-term solutions. The stigmatization of vaginal health issues and lack of awareness in developing regions also challenge market penetration. Moreover, stringent regulatory requirements and the high costs associated with drug development can impede the entry of novel therapeutics into the market. Areas ripe for innovation include exploring the microbiome's role in maintaining vaginal health and developing novel prebiotic and probiotic treatments, while also harnessing digital health tools for early diagnosis and improved patient compliance. The bacterial vaginosis drugs market is competitive and dynamic, requiring continuous adaptation to evolving scientific discoveries and patient needs. A customer-centric approach, prioritizing patient education and collaboration with healthcare professionals, can drive business growth and ensure effective market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bacterial Vaginosis Drugs Market

The Bacterial Vaginosis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of bacterial vaginosis among women of reproductive age globally
    • Growing awareness and demand for effective treatments for bacterial vaginosis
    • Advancements in pharmaceutical research and development for bacterial vaginosis drugs
    • Expansion of healthcare infrastructure in developing regions supporting bacterial vaginosis treatments
  • Market Restraints
    • Limited awareness and misdiagnosis in emerging markets affecting treatment rates
    • Stigma and social taboos surrounding bacterial vaginosis impacting patient willingness to seek treatment
  • Market Opportunities
    • Development of targeted marketing strategies to raise awareness about bacterial vaginosis and available treatments among women
    • Leveraging telemedicine platforms to provide easier access to bacterial vaginosis consultations and prescriptions
    • Creating educational campaigns to destigmatize bacterial vaginosis and encourage timely medical intervention
  • Market Challenges
    • Inconsistent reimbursement policies for bacterial vaginosis treatments across different healthcare systems
    • Intense competition from generic drugs reduces market share and profitability for branded bacterial vaginosis drug manufacturers

Porter's Five Forces: A Strategic Tool for Navigating the Bacterial Vaginosis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bacterial Vaginosis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bacterial Vaginosis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bacterial Vaginosis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bacterial Vaginosis Drugs Market

A detailed market share analysis in the Bacterial Vaginosis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bacterial Vaginosis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bacterial Vaginosis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bacterial Vaginosis Drugs Market

A strategic analysis of the Bacterial Vaginosis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bacterial Vaginosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Bacterial Vaginosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Over-the-counter Drugs and Prescription Drugs. The Over-the-counter Drugs is further studied across Antiseptics and Probiotics. The Prescription Drugs is further studied across Oral Antibiotics and Topical Antibiotics.
  • Based on Drug Form, market is studied across Capsules, Gels, and Tablets. The Gels is further studied across Medicated Gels and Non-medicated Gels. The Tablets is further studied across Effervescent Tablets, Extended Release Tablets, and Immediate Release Tablets.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Demographics, market is studied across Adults, Elders, and Teenagers.
  • Based on End User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bacterial vaginosis among women of reproductive age globally
      • 5.1.1.2. Growing awareness and demand for effective treatments for bacterial vaginosis
      • 5.1.1.3. Advancements in pharmaceutical research and development for bacterial vaginosis drugs
      • 5.1.1.4. Expansion of healthcare infrastructure in developing regions supporting bacterial vaginosis treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited awareness and misdiagnosis in emerging markets affecting treatment rates
      • 5.1.2.2. Stigma and social taboos surrounding bacterial vaginosis impacting patient willingness to seek treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of targeted marketing strategies to raise awareness about bacterial vaginosis and available treatments among women
      • 5.1.3.2. Leveraging telemedicine platforms to provide easier access to bacterial vaginosis consultations and prescriptions
      • 5.1.3.3. Creating educational campaigns to destigmatize bacterial vaginosis and encourage timely medical intervention
    • 5.1.4. Challenges
      • 5.1.4.1. Inconsistent reimbursement policies for bacterial vaginosis treatments across different healthcare systems
      • 5.1.4.2. Intense competition from generic drugs reduces market share and profitability for branded bacterial vaginosis drug manufacturers
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bacterial Vaginosis Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Over-the-counter Drugs
    • 6.2.1. Antiseptics
    • 6.2.2. Probiotics
  • 6.3. Prescription Drugs
    • 6.3.1. Oral Antibiotics
    • 6.3.2. Topical Antibiotics

7. Bacterial Vaginosis Drugs Market, by Drug Form

  • 7.1. Introduction
  • 7.2. Capsules
  • 7.3. Gels
    • 7.3.1. Medicated Gels
    • 7.3.2. Non-medicated Gels
  • 7.4. Tablets
    • 7.4.1. Effervescent Tablets
    • 7.4.2. Extended Release Tablets
    • 7.4.3. Immediate Release Tablets

8. Bacterial Vaginosis Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Bacterial Vaginosis Drugs Market, by Patient Demographics

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Elders
  • 9.4. Teenagers

10. Bacterial Vaginosis Drugs Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Americas Bacterial Vaginosis Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Bacterial Vaginosis Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Bacterial Vaginosis Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca plc
  • 6. Bayer AG
  • 7. Bristol-Myers Squibb Company
  • 8. Eli Lilly and Company
  • 9. Gilead Sciences, Inc.
  • 10. GlaxoSmithKline plc
  • 11. Johnson & Johnson
  • 12. Merck & Co., Inc.
  • 13. Mylan N.V.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Roche Holding AG
  • 17. Sanofi
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BACTERIAL VAGINOSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BACTERIAL VAGINOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BACTERIAL VAGINOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BACTERIAL VAGINOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BACTERIAL VAGINOSIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TOPICAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY MEDICATED GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY NON-MEDICATED GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY EFFERVESCENT TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ELDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TEENAGERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 279. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 297. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 306. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 313. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 315. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GELS, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 322. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 324. QATAR BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR BACTERIAL VAGINOSIS DRUGS MARKET